JP2012525398A - 眼科障害を治療するためのトコトリエノールの局所、眼周囲または眼内使用 - Google Patents
眼科障害を治療するためのトコトリエノールの局所、眼周囲または眼内使用 Download PDFInfo
- Publication number
- JP2012525398A JP2012525398A JP2012508607A JP2012508607A JP2012525398A JP 2012525398 A JP2012525398 A JP 2012525398A JP 2012508607 A JP2012508607 A JP 2012508607A JP 2012508607 A JP2012508607 A JP 2012508607A JP 2012525398 A JP2012525398 A JP 2012525398A
- Authority
- JP
- Japan
- Prior art keywords
- tocotrienol
- disease
- ophthalmic
- alpha
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930003802 tocotrienol Natural products 0.000 title claims abstract description 87
- 239000011731 tocotrienol Substances 0.000 title claims abstract description 87
- 235000019148 tocotrienols Nutrition 0.000 title claims abstract description 87
- 230000000699 topical effect Effects 0.000 title claims abstract description 53
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 title claims description 55
- 239000000203 mixture Substances 0.000 claims abstract description 202
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 163
- RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 claims abstract description 156
- 238000009472 formulation Methods 0.000 claims abstract description 126
- 229940064063 alpha tocotrienol Drugs 0.000 claims abstract description 117
- 235000019145 α-tocotrienol Nutrition 0.000 claims abstract description 117
- 239000011730 α-tocotrienol Substances 0.000 claims abstract description 117
- RZFHLOLGZPDCHJ-XZXLULOTSA-N α-Tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C RZFHLOLGZPDCHJ-XZXLULOTSA-N 0.000 claims abstract description 112
- OTXNTMVVOOBZCV-UHFFFAOYSA-N 2R-gamma-tocotrienol Natural products OC1=C(C)C(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-UHFFFAOYSA-N 0.000 claims abstract description 75
- 238000000034 method Methods 0.000 claims abstract description 69
- 208000014674 injury Diseases 0.000 claims abstract description 57
- 150000002148 esters Chemical class 0.000 claims abstract description 51
- OTXNTMVVOOBZCV-YMCDKREISA-N gamma-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CCc2c1 OTXNTMVVOOBZCV-YMCDKREISA-N 0.000 claims abstract description 39
- OTXNTMVVOOBZCV-WAZJVIJMSA-N γ-tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-WAZJVIJMSA-N 0.000 claims abstract description 39
- 235000019150 γ-tocotrienol Nutrition 0.000 claims abstract description 39
- 239000011722 γ-tocotrienol Substances 0.000 claims abstract description 39
- 230000008733 trauma Effects 0.000 claims abstract description 37
- ODADKLYLWWCHNB-UHFFFAOYSA-N 2R-delta-tocotrienol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-UHFFFAOYSA-N 0.000 claims abstract description 36
- BTNBMQIHCRIGOU-UHFFFAOYSA-N delta-tocotrienol Natural products CC(=CCCC(=CCCC(=CCCOC1(C)CCc2cc(O)cc(C)c2O1)C)C)C BTNBMQIHCRIGOU-UHFFFAOYSA-N 0.000 claims abstract description 36
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 36
- ODADKLYLWWCHNB-LDYBVBFYSA-N δ-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-LDYBVBFYSA-N 0.000 claims abstract description 36
- 235000019144 δ-tocotrienol Nutrition 0.000 claims abstract description 36
- 239000011729 δ-tocotrienol Substances 0.000 claims abstract description 36
- FGYKUFVNYVMTAM-UHFFFAOYSA-N (R)-2,5,8-trimethyl-2-(4,8,12-trimethyl-trideca-3t,7t,11-trienyl)-chroman-6-ol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-UHFFFAOYSA-N 0.000 claims abstract description 34
- FGYKUFVNYVMTAM-YMCDKREISA-N beta-Tocotrienol Natural products Oc1c(C)c2c(c(C)c1)O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CC2 FGYKUFVNYVMTAM-YMCDKREISA-N 0.000 claims abstract description 34
- FGYKUFVNYVMTAM-MUUNZHRXSA-N epsilon-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-MUUNZHRXSA-N 0.000 claims abstract description 34
- FGYKUFVNYVMTAM-WAZJVIJMSA-N β-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-WAZJVIJMSA-N 0.000 claims abstract description 34
- 235000019151 β-tocotrienol Nutrition 0.000 claims abstract description 34
- 239000011723 β-tocotrienol Substances 0.000 claims abstract description 34
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 29
- 208000012268 mitochondrial disease Diseases 0.000 claims abstract description 28
- 239000003732 agents acting on the eye Substances 0.000 claims abstract description 23
- 229940125702 ophthalmic agent Drugs 0.000 claims abstract description 23
- 230000009467 reduction Effects 0.000 claims abstract description 12
- 230000002265 prevention Effects 0.000 claims abstract description 11
- 208000035475 disorder Diseases 0.000 claims description 102
- 208000001992 Autosomal Dominant Optic Atrophy Diseases 0.000 claims description 76
- 201000004569 Blindness Diseases 0.000 claims description 74
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims description 73
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 claims description 73
- 230000004393 visual impairment Effects 0.000 claims description 65
- 201000010099 disease Diseases 0.000 claims description 56
- 230000000750 progressive effect Effects 0.000 claims description 52
- 208000002780 macular degeneration Diseases 0.000 claims description 40
- 208000011580 syndromic disease Diseases 0.000 claims description 38
- 230000001684 chronic effect Effects 0.000 claims description 35
- 230000007812 deficiency Effects 0.000 claims description 34
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 31
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims description 28
- 210000001508 eye Anatomy 0.000 claims description 28
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims description 28
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 27
- 230000006378 damage Effects 0.000 claims description 26
- 206010033799 Paralysis Diseases 0.000 claims description 25
- 208000018737 Parkinson disease Diseases 0.000 claims description 24
- 208000014644 Brain disease Diseases 0.000 claims description 23
- 208000032274 Encephalopathy Diseases 0.000 claims description 23
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 22
- -1 alpha-tocotrienol ester Chemical class 0.000 claims description 22
- 208000018769 loss of vision Diseases 0.000 claims description 22
- 231100000864 loss of vision Toxicity 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 210000003205 muscle Anatomy 0.000 claims description 21
- 102000014461 Ataxins Human genes 0.000 claims description 20
- 108010078286 Ataxins Proteins 0.000 claims description 20
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 20
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 20
- 206010030875 ophthalmoplegia Diseases 0.000 claims description 20
- 208000010412 Glaucoma Diseases 0.000 claims description 19
- 208000027073 Stargardt disease Diseases 0.000 claims description 19
- 208000027418 Wounds and injury Diseases 0.000 claims description 19
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 19
- 208000017442 Retinal disease Diseases 0.000 claims description 17
- 208000027653 severe early-childhood-onset retinal dystrophy Diseases 0.000 claims description 17
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims description 16
- 208000030768 Optic nerve injury Diseases 0.000 claims description 16
- 201000009028 early myoclonic encephalopathy Diseases 0.000 claims description 16
- 239000000835 fiber Substances 0.000 claims description 16
- 208000021090 palsy Diseases 0.000 claims description 16
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims description 14
- 206010038923 Retinopathy Diseases 0.000 claims description 14
- 208000006011 Stroke Diseases 0.000 claims description 14
- 208000006443 lactic acidosis Diseases 0.000 claims description 14
- 208000024827 Alzheimer disease Diseases 0.000 claims description 13
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 13
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 13
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 12
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 11
- 206010034010 Parkinsonism Diseases 0.000 claims description 11
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims description 11
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 11
- 206010030113 Oedema Diseases 0.000 claims description 10
- 230000009286 beneficial effect Effects 0.000 claims description 10
- 208000001749 optic atrophy Diseases 0.000 claims description 10
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 9
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 9
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims description 9
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 9
- 208000028226 Krabbe disease Diseases 0.000 claims description 9
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 claims description 9
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 9
- 208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 claims description 8
- 102000015782 Electron Transport Complex III Human genes 0.000 claims description 8
- 108010024882 Electron Transport Complex III Proteins 0.000 claims description 8
- 208000014060 Niemann-Pick disease Diseases 0.000 claims description 8
- 239000003889 eye drop Substances 0.000 claims description 8
- 238000011476 stem cell transplantation Methods 0.000 claims description 8
- 150000003612 tocotrienol derivatives Polymers 0.000 claims description 8
- 102000007371 Ataxin-3 Human genes 0.000 claims description 7
- 102100026784 Myelin proteolipid protein Human genes 0.000 claims description 7
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 claims description 7
- 230000001154 acute effect Effects 0.000 claims description 7
- 208000006136 Leigh Disease Diseases 0.000 claims description 6
- 230000000642 iatrogenic effect Effects 0.000 claims description 6
- 238000002647 laser therapy Methods 0.000 claims description 6
- 208000030159 metabolic disease Diseases 0.000 claims description 6
- 238000002428 photodynamic therapy Methods 0.000 claims description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 5
- 208000017507 Leigh syndrome Diseases 0.000 claims description 5
- 229930195712 glutamate Natural products 0.000 claims description 5
- 229940113601 irrigation solution Drugs 0.000 claims description 5
- 235000001968 nicotinic acid Nutrition 0.000 claims description 5
- 239000011664 nicotinic acid Substances 0.000 claims description 5
- 230000004224 protection Effects 0.000 claims description 5
- 208000032253 retinal ischemia Diseases 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- 206010057410 Hippus Diseases 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 4
- 229940009098 aspartate Drugs 0.000 claims description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 4
- 230000004060 metabolic process Effects 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 230000006735 deficit Effects 0.000 claims description 2
- 150000003773 α-tocotrienols Polymers 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims 3
- 208000022873 Ocular disease Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 abstract description 21
- 229940068778 tocotrienols Drugs 0.000 abstract description 21
- 150000001875 compounds Chemical class 0.000 description 31
- 239000003981 vehicle Substances 0.000 description 25
- 208000024891 symptom Diseases 0.000 description 24
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 17
- 230000037396 body weight Effects 0.000 description 16
- 229930003799 tocopherol Natural products 0.000 description 14
- 239000011732 tocopherol Substances 0.000 description 14
- 210000001328 optic nerve Anatomy 0.000 description 11
- 108020005196 Mitochondrial DNA Proteins 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 125000002640 tocopherol group Chemical class 0.000 description 9
- 235000019149 tocopherols Nutrition 0.000 description 9
- 239000013543 active substance Substances 0.000 description 8
- 230000004438 eyesight Effects 0.000 description 8
- 150000003904 phospholipids Chemical class 0.000 description 8
- 230000002207 retinal effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 229930003427 Vitamin E Natural products 0.000 description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 7
- 210000001525 retina Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 235000019165 vitamin E Nutrition 0.000 description 7
- 239000011709 vitamin E Substances 0.000 description 7
- 229940046009 vitamin E Drugs 0.000 description 7
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 7
- 230000005856 abnormality Effects 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 230000000007 visual effect Effects 0.000 description 6
- 239000000607 artificial tear Substances 0.000 description 5
- 230000004456 color vision Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 210000003733 optic disk Anatomy 0.000 description 5
- 208000020911 optic nerve disease Diseases 0.000 description 5
- 238000012014 optical coherence tomography Methods 0.000 description 5
- 210000003994 retinal ganglion cell Anatomy 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 235000010384 tocopherol Nutrition 0.000 description 5
- 229960001295 tocopherol Drugs 0.000 description 5
- 238000011200 topical administration Methods 0.000 description 5
- 206010003591 Ataxia Diseases 0.000 description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 4
- 206010013774 Dry eye Diseases 0.000 description 4
- 206010025421 Macule Diseases 0.000 description 4
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 4
- 206010061323 Optic neuropathy Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940012356 eye drops Drugs 0.000 description 4
- 230000004424 eye movement Effects 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 201000006366 primary open angle glaucoma Diseases 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 230000000472 traumatic effect Effects 0.000 description 4
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 3
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- 208000028389 Nerve injury Diseases 0.000 description 3
- 208000035965 Postoperative Complications Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000000030 antiglaucoma agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 235000019864 coconut oil Nutrition 0.000 description 3
- 235000017471 coenzyme Q10 Nutrition 0.000 description 3
- 229940110767 coenzyme Q10 Drugs 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 210000002969 egg yolk Anatomy 0.000 description 3
- 210000000744 eyelid Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008764 nerve damage Effects 0.000 description 3
- 206010029864 nystagmus Diseases 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 208000026553 Autosomal dominant optic atrophy, classic form Diseases 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- 208000006992 Color Vision Defects Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 208000003164 Diplopia Diseases 0.000 description 2
- 208000020564 Eye injury Diseases 0.000 description 2
- 208000032578 Inherited retinal disease Diseases 0.000 description 2
- 208000035719 Maculopathy Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000032430 Retinal dystrophy Diseases 0.000 description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 206010047531 Visual acuity reduced Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000035110 classic form autosomal dominant optic atrophy Diseases 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 208000029444 double vision Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 231100000040 eye damage Toxicity 0.000 description 2
- 201000006321 fundus dystrophy Diseases 0.000 description 2
- 208000017532 inherited retinal dystrophy Diseases 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- 230000002747 voluntary effect Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010002261 Androgen deficiency Diseases 0.000 description 1
- 206010063292 Brain stem syndrome Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 208000010354 Coenzyme Q10 deficiency Diseases 0.000 description 1
- 208000036693 Color-vision disease Diseases 0.000 description 1
- 206010010051 Colour blindness acquired Diseases 0.000 description 1
- 206010011168 Cortical dysfunction Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 108091065810 E family Proteins 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 208000001351 Epiretinal Membrane Diseases 0.000 description 1
- 102000003869 Frataxin Human genes 0.000 description 1
- 108090000217 Frataxin Proteins 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000022569 Hypohidrotic ectodermal dysplasia-hypothyroidism-ciliary dyskinesia syndrome Diseases 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 235000002296 Ilex sandwicensis Nutrition 0.000 description 1
- 235000002294 Ilex volkensiana Nutrition 0.000 description 1
- 208000010415 Low Vision Diseases 0.000 description 1
- 208000009564 MELAS Syndrome Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010052641 Mitochondrial DNA mutation Diseases 0.000 description 1
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 208000024571 Pick disease Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010067206 Postural reflex impairment Diseases 0.000 description 1
- 206010037213 Psychomotor retardation Diseases 0.000 description 1
- 208000002367 Retinal Perforations Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000022758 Sorsby fundus dystrophy Diseases 0.000 description 1
- 208000004350 Strabismus Diseases 0.000 description 1
- 108060007963 Surf-1 Proteins 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 230000004598 abnormal eye movement Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001384 anti-glaucoma Effects 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 229940073464 benzododecinium bromide Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229940035183 bion tears Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical group C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 201000007254 color blindness Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 206010010121 compartment syndrome Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- GJJVAFUKOBZPCB-HQLRYZJNSA-N desmethyl tocotrienol Chemical compound OC1=CC=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-HQLRYZJNSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940119743 dextran 70 Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940093476 ethylene glycol Drugs 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014188 hereditary optic neuropathy Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000029233 macular holes Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 230000006724 microglial activation Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 230000007433 nerve pathway Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000003565 oculomotor Effects 0.000 description 1
- 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 description 1
- 229940095790 ophthalmic irrigation solution Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000012169 petroleum derived wax Substances 0.000 description 1
- 235000019381 petroleum wax Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 125000001189 phytyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])([H])[C@@](C([H])([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])[C@@](C([H])([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 208000007260 recurrent myoglobinuria Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 210000001116 retinal neuron Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 description 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000003900 succinic acid esters Chemical class 0.000 description 1
- 229940036266 tears naturale Drugs 0.000 description 1
- 125000003036 tocotrienol group Chemical group 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 230000008403 visual deficit Effects 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21476009P | 2009-04-28 | 2009-04-28 | |
| US61/214,760 | 2009-04-28 | ||
| PCT/US2010/032622 WO2010126910A1 (en) | 2009-04-28 | 2010-04-27 | Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012525398A true JP2012525398A (ja) | 2012-10-22 |
| JP2012525398A5 JP2012525398A5 (enExample) | 2013-06-13 |
Family
ID=43032521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012508607A Pending JP2012525398A (ja) | 2009-04-28 | 2010-04-27 | 眼科障害を治療するためのトコトリエノールの局所、眼周囲または眼内使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20120136048A1 (enExample) |
| EP (1) | EP2424360A4 (enExample) |
| JP (1) | JP2012525398A (enExample) |
| BR (1) | BRPI1015006A2 (enExample) |
| CA (1) | CA2760357A1 (enExample) |
| WO (1) | WO2010126910A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024505651A (ja) * | 2020-10-08 | 2024-02-07 | グローバル サイエンティフィック | トコトリエノール類誘導体、その方法及び使用 |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2583084C (en) | 2003-09-19 | 2010-12-07 | Galileo Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
| EP2564842A1 (en) * | 2005-06-01 | 2013-03-06 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| JP5374162B2 (ja) | 2006-02-22 | 2013-12-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節 |
| CA2704473C (en) | 2007-11-06 | 2016-10-04 | Edison Pharmaceuticals, Inc. | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
| EP2237664A4 (en) | 2008-01-08 | 2013-05-22 | Edison Pharmaceuticals Inc | (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES |
| WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| US8716486B2 (en) * | 2008-06-25 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| MX363223B (es) | 2008-09-10 | 2019-03-15 | Bioelectron Tech Corp | Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox. |
| CA2740773A1 (en) | 2008-10-14 | 2010-04-22 | Edison Pharmaceuticals, Inc. | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| CA2974482C (en) | 2008-10-28 | 2019-10-29 | Bioelectron Technology Corporation | High purity alpha tocotrienol quinone and processes for preparing same |
| NO2424495T3 (enExample) | 2009-04-28 | 2018-06-16 | ||
| SI2470168T1 (en) * | 2009-08-26 | 2018-05-31 | Bioelectron Technology Corporation | Procedures for the prevention and treatment of brain ischemia |
| WO2012158018A2 (en) * | 2011-05-18 | 2012-11-22 | Malaysian Palm Oil Board | Compositions comprising extracts or materials derived from palm oil vegetation liguor for inhibition of vision loss due to angiogenesis and method of preparation thereof |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| CN114702406B (zh) | 2014-12-16 | 2025-02-25 | Ptc医疗公司 | 化合物的多晶型和无定形形式 |
| EP3390377A1 (en) | 2015-12-16 | 2018-10-24 | BioElectron Technology Corporation | Improved methods for enriching alpha-tocotrienol from mixed tocol compositions |
| AU2016369616B2 (en) | 2015-12-17 | 2021-03-25 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| WO2018136871A1 (en) * | 2017-01-20 | 2018-07-26 | Ohio State Innovation Foundation | Topical tocotrienol compositions and methods of increasing skin stem cells |
| MY210324A (en) | 2018-10-17 | 2025-09-11 | Ptc Therapeutics Inc | 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING a-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS |
| MX2024000445A (es) | 2021-07-08 | 2024-04-05 | Ptc Therapeutics Inc | Composiciones farmaceuticas que comprenden 2,3,5-trimetil-6-nonilc iclohexa-2,5-dieno-1,4-diona. |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09157165A (ja) * | 1995-12-11 | 1997-06-17 | Lion Corp | 点眼薬及び白内障の遅延・治療用剤 |
| JPH10109934A (ja) * | 1996-10-04 | 1998-04-28 | Sekisui Chem Co Ltd | 炎症性眼疾患用剤 |
| JP2002308768A (ja) * | 2001-02-08 | 2002-10-23 | Fuji Chem Ind Co Ltd | トコトリエノールを有効成分とする血管新生阻害剤、細胞増殖阻害剤、管腔形成阻害剤及びｆｇｆ阻害剤並びに食品或いは食品添加物 |
| JP2004323486A (ja) * | 2003-04-30 | 2004-11-18 | National Institute Of Advanced Industrial & Technology | 網膜及び／又はブドウ膜疾患の予防乃至治療用点眼薬 |
| US20050065099A1 (en) * | 2003-09-19 | 2005-03-24 | Gail Walkinshaw | Treatment of mitochondrial diseases |
| JP2005528441A (ja) * | 2002-05-30 | 2005-09-22 | オクラホマ メディカル リサーチ ファウンデーション | 運動性能及び／又は持久力を増強するための方法 |
| JP2012505244A (ja) * | 2008-10-09 | 2012-03-01 | ラムズコア， インコーポレイテッド | ドライアイ症候群の処置のための組成物および方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5217992A (en) * | 1989-10-04 | 1993-06-08 | Bristol-Myers Squibb Company | Tocotrienols in the treatment of hypercholesterolemia, hyperlipidemia and thromboembolic disorders |
| US20060127505A1 (en) * | 2002-01-16 | 2006-06-15 | David Haines | Anti-inflammatory formulations |
| ES2532997T3 (es) * | 2005-04-22 | 2015-04-06 | Elizabeth Stuart | Uso de tocotrienoles de vitamina E para la inhibición del patógeno intracelular obligado Chlamydia |
| US20070092502A1 (en) * | 2005-09-01 | 2007-04-26 | Allergan, Inc. | Method of Treating Glaucoma |
| JP5374162B2 (ja) * | 2006-02-22 | 2013-12-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節 |
-
2010
- 2010-04-27 JP JP2012508607A patent/JP2012525398A/ja active Pending
- 2010-04-27 US US13/266,240 patent/US20120136048A1/en not_active Abandoned
- 2010-04-27 EP EP10770214A patent/EP2424360A4/en not_active Withdrawn
- 2010-04-27 WO PCT/US2010/032622 patent/WO2010126910A1/en not_active Ceased
- 2010-04-27 BR BRPI1015006A patent/BRPI1015006A2/pt not_active IP Right Cessation
- 2010-04-27 CA CA2760357A patent/CA2760357A1/en not_active Abandoned
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09157165A (ja) * | 1995-12-11 | 1997-06-17 | Lion Corp | 点眼薬及び白内障の遅延・治療用剤 |
| JPH10109934A (ja) * | 1996-10-04 | 1998-04-28 | Sekisui Chem Co Ltd | 炎症性眼疾患用剤 |
| JP2002308768A (ja) * | 2001-02-08 | 2002-10-23 | Fuji Chem Ind Co Ltd | トコトリエノールを有効成分とする血管新生阻害剤、細胞増殖阻害剤、管腔形成阻害剤及びｆｇｆ阻害剤並びに食品或いは食品添加物 |
| JP2005528441A (ja) * | 2002-05-30 | 2005-09-22 | オクラホマ メディカル リサーチ ファウンデーション | 運動性能及び／又は持久力を増強するための方法 |
| JP2004323486A (ja) * | 2003-04-30 | 2004-11-18 | National Institute Of Advanced Industrial & Technology | 網膜及び／又はブドウ膜疾患の予防乃至治療用点眼薬 |
| US20050065099A1 (en) * | 2003-09-19 | 2005-03-24 | Gail Walkinshaw | Treatment of mitochondrial diseases |
| JP2012505244A (ja) * | 2008-10-09 | 2012-03-01 | ラムズコア， インコーポレイテッド | ドライアイ症候群の処置のための組成物および方法 |
Non-Patent Citations (2)
| Title |
|---|
| CAN J OPHTHALMOL, vol. 42, JPN6014020271, 2007, pages 425 - 438, ISSN: 0002814549 * |
| LIFE SCIENCES, vol. 78, JPN6014020269, 2006, pages 2088 - 2098, ISSN: 0002814548 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024505651A (ja) * | 2020-10-08 | 2024-02-07 | グローバル サイエンティフィック | トコトリエノール類誘導体、その方法及び使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010126910A1 (en) | 2010-11-04 |
| EP2424360A1 (en) | 2012-03-07 |
| US20120136048A1 (en) | 2012-05-31 |
| EP2424360A4 (en) | 2012-10-03 |
| BRPI1015006A2 (pt) | 2019-09-24 |
| CA2760357A1 (en) | 2010-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012525398A (ja) | 眼科障害を治療するためのトコトリエノールの局所、眼周囲または眼内使用 | |
| JP2017193594A (ja) | 眼科疾患を治療するためのトコトリエノールキノンの製剤 | |
| JP6266674B2 (ja) | 眼疾患の処置のためのキノンの製剤 | |
| AU2011245384B9 (en) | Formulations of quinones for the treatment of ophthalmic diseases | |
| CN116850182A (zh) | 用于治疗近视的方法和药物组合物 | |
| US8658624B2 (en) | Pharmaceutical compositions for preventing and treating eye pathologies | |
| US12102640B2 (en) | Use of dopamine and serotonin receptor antagonists for treatment in a subject with retinal degeneration | |
| TW201406382A (zh) | 具視網膜保護功能之複方組成物及應用 | |
| Pardines et al. | Bilateral choroidal effusion after selective laser trabeculoplasty | |
| US5883127A (en) | Use of lower alkanoyl L-carnitines to produce a medicament suitable for the therapeutic treatment of retinopathies | |
| JP7659940B2 (ja) | ビンポセチンを用いる近視の治療方法 | |
| EP3682867B1 (en) | Lutein-containing ophthalmic composition | |
| Mehkri et al. | The effects of lutein and zeaxanthin (Lute-gen®) supplementation, with and without natural mixed carotenoids on macular pigment optical density in healthy adult subjects: A randomized, double-blind, placebo-controlled study | |
| Kartasasmita et al. | The effectiveness of continuous intravitreal adrenaline as mydriatic adjuvant on pars plana vitrectomy in diabetic patient, a randomized clinical trial | |
| RU2776877C1 (ru) | Способ лечения поздней стадии неэкссудативной формы возрастной макулярной дегенерации | |
| Konovalova et al. | On the treatment of degeneration of the macula and posterior pole | |
| US20050038103A1 (en) | Uses of dorzolamide | |
| HK40034331A (en) | Use of pilocarpine hydrochloride for the treatment of presbyopia | |
| HK40034331B (en) | Use of pilocarpine hydrochloride for the treatment of presbyopia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130424 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130424 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140520 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140819 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140826 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20141215 |